Get the Stockscreener App
9.2717
3.22%
-0.3083
Mersana Therapeutics Inc stock is traded at $9.2717, with a volume of 24,940.
It is down -3.22% in the last 24 hours and up +11.98% over the past month.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
See More
Previous Close:
$9.58
Open:
$9.54
24h Volume:
24,940
Relative Volume:
0.36
Market Cap:
$46.31M
Revenue:
$34.77M
Net Income/Loss:
$-74.04M
P/E Ratio:
-1.1567
EPS:
-8.0157
Net Cash Flow:
$-79.76M
1W Performance:
-12.45%
1M Performance:
+11.98%
6M Performance:
-6.75%
1Y Performance:
-79.62%
1-Day Range:
$8.96
$9.59
1-Week Range:
$8.96
$10.60
52-Week Range:
$5.21
$70.75
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Name
Mersana Therapeutics Inc
Sector
Industry
Phone
617-498-0020
Address
840 MEMORIAL DRIVE, CAMBRIDGE
Compare MRSN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
9.28 | 47.81M | 34.77M | -74.04M | -79.76M | -8.0157 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.08 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.99 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.26 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.85 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.78 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-25 | Initiated | William Blair | Outperform |
| Nov-15-24 | Resumed | Citigroup | Buy |
| Mar-19-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Feb-29-24 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-29-24 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-29-24 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-04-23 | Upgrade | Citigroup | Neutral → Buy |
| Jul-28-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-27-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-27-23 | Downgrade | Citigroup | Buy → Neutral |
| Jul-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-27-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-27-23 | Downgrade | Truist | Buy → Hold |
| Jul-27-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-16-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-15-23 | Initiated | Guggenheim | Buy |
| Mar-16-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-20-23 | Initiated | Citigroup | Buy |
| Nov-21-22 | Initiated | Truist | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Aug-30-21 | Initiated | H.C. Wainwright | Buy |
| Mar-31-21 | Initiated | Credit Suisse | Neutral |
| Dec-03-20 | Initiated | Stifel | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Apr-29-20 | Initiated | BTIG Research | Buy |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-11-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| May-08-18 | Initiated | Robert W. Baird | Outperform |
| Mar-19-18 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Mersana Therapeutics Inc Stock (MRSN) Latest News
How cyclical is Mersana Therapeutics Inc. (0M4) stock compared to rivalsMarket Sentiment Report & Daily Momentum Trading Reports - newser.com
Can Mersana Therapeutics Inc. (0M4) stock stage a strong rebound this quarterJuly 2025 Reactions & AI Powered Market Entry Ideas - newser.com
Heatmap analysis for Mersana Therapeutics Inc. and competitorsEarnings Trend Report & Low Risk Entry Point Tips - newser.com
News impact scoring models applied to Mersana Therapeutics Inc.Earnings Summary Report & Verified High Yield Trade Plans - newser.com
Using data filters to optimize entry into Mersana Therapeutics Inc.Fed Meeting & Real-Time Buy Signal Alerts - newser.com
Can you recover from losses in Mersana Therapeutics Inc.Weekly Stock Recap & Long-Term Growth Plans - newser.com
How Mersana Therapeutics Inc. stock benefits from global expansionFed Meeting & Daily Risk Controlled Trade Plans - newser.com
Can Mersana Therapeutics Inc. (0M4) stock sustain breakout momentumMarket Activity Recap & Daily Stock Trend Watchlist - newser.com
Price action breakdown for Mersana Therapeutics Inc.2025 Key Highlights & Community Verified Swing Trade Signals - newser.com
How Mersana Therapeutics Inc. (0M4) stock responds to job market shifts2025 Momentum Check & Weekly Chart Analysis and Guides - newser.com
Why Mersana Therapeutics Inc. stock remains a top recommendationWeekly Earnings Recap & Technical Entry and Exit Alerts - newser.com
Why Mersana Therapeutics Inc. stock could rally in 2025Earnings Miss & Community Supported Trade Ideas - newser.com
Detecting price anomalies in Mersana Therapeutics Inc. with AIJuly 2025 Market Mood & Precise Buy Zone Tips - newser.com
Earnings visualization tools for Mersana Therapeutics Inc.Market Trend Report & Capital Protection Trade Alerts - newser.com
What momentum shifts mean for Mersana Therapeutics Inc.July 2025 Pullbacks & Daily Stock Trend Watchlist - newser.com
How Mersana Therapeutics Inc. (0M4) stock reacts to weak economyTrade Volume Report & High Conviction Buy Zone Picks - newser.com
Is Mersana Therapeutics Inc. stock ready for a breakoutMarket Performance Recap & Reliable Breakout Forecasts - newser.com
Does Mersana Therapeutics Inc. qualify in momentum factor screeningShare Buyback & Free Reliable Trade Execution Plans - newser.com
Should you hold or exit Mersana Therapeutics Inc. now2025 AllTime Highs & Risk Controlled Stock Alerts - newser.com
Mersana Therapeutics Inc Stock (MRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):